Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Clinical trial NCT03300843 · TERMINATED
Trial details
- NCT number
- NCT03300843
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-11
- Primary completion
- 2019-07-09
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.